Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro
| Autor: | Siqiang Niu, Hanbing Yu, Xian Chen, Deyu Ma, Menglu Wu, Qiuxia Lin, Shifeng Huang, Hua Zou |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
Avibactam Stenotrophomonas maltophilia lcsh:QR1-502 Ceftazidime Aztreonam Microbial Sensitivity Tests Biology Microbiology lcsh:Microbiology 03 medical and health sciences chemistry.chemical_compound Antibiotic resistance Drug Resistance Multiple Bacterial medicine Humans 030304 developmental biology 0303 health sciences 030306 microbiology Ceftazidime-avibactam Broth microdilution Minimum inhibitory concentrations Ceftazidime/avibactam biology.organism_classification Aztreonam-avibactam Anti-Bacterial Agents Drug Combinations chemistry Parasitology Gram-Negative Bacterial Infections Azabicyclo Compounds medicine.drug Research Article |
| Zdroj: | BMC Microbiology BMC Microbiology, Vol 21, Iss 1, Pp 1-6 (2021) |
| ISSN: | 1471-2180 |
| Popis: | Background Treatment options for Stenotrophomonas maltophilia (S. maltophilia) infections were limited. We assessed the efficacy of ceftazidime (CAZ), ceftazidime-avibactam (CAZ-AVI), aztreonam (ATM), and aztreonam-avibactam (ATM-AVI) against a selection of 76 S. maltophilia out of the 1179 strains isolated from the First Affiliated Hospital of Chongqing Medical University during 2011–2018. Methods We investigated the antimicrobial resistance profiles of the 1179 S. maltophilia clinical isolates from the first affiliated hospital of Chongqing Medical University during 2011–2018, a collection of 76 isolates were selected for further study of microbiological characterization. Minimum inhibitory concentrations (MICs) of CAZ, CAZ-AVI, ATM and ATM-AVI were determined via the broth microdilution method. We deemed that CAZ-AVI or ATM-AVI was more active in vitro than CAZ or ATM alone when CAZ-AVI or ATM-AVI led to a category change from “Resistant” or “Intermediate” with CAZ or ATM alone to “Susceptible” with CAZ-AVI or ATM-AVI, or if the MIC of CAZ-AVI or ATM-AVI was at least 4-fold lower than the MIC of CAZ or ATM alone. Results For the 76 clinical isolates included in the study, MICs of CAZ, ATM, CAZ-AVI and ATM-AVI ranged from 0.03–64, 1–1024, 0.016–64, and 0.06–64 μg/mL, respectively. In combined therapy, AVI was active at restoring the activity of 48.48% (16/33) and 89.71% (61/68) of S. maltophilia to CAZ and ATM, respectively. Furthermore, CAZ-AVI showed better results in terms of the proportion of susceptible isolates (77.63% vs. 56.58%, P P P P Conclusions AVI potentiated the activity of both CAZ and ATM against S. maltophilia clinical isolates in vitro. We demonstrated that CAZ-AVI and ATM-AVI are both useful therapeutic options to treat infections caused by S. maltophilia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink